NATURE Article: Neuroimmune cardiovascular interfaces control atherosclerosis

2024-08-13

Author's information: Sarajo K. Mohanta, Li Peng, Yuanfang Li, Shu Lu, Ting Sun, Lorenzo Carnevale, Marialuisa Perrotta, Zhe Ma, Benjamin F?rstera, Karen Stanic, Chuankai Zhang, Xi Zhang, Piotr Szczepaniak, Mariaelvy Bianchini, Borhan R. Saeed, Raimondo Carnevale, Desheng Hu, Ryszard Nosalski, Fabio Pallante, Michael Beer, Donato Santovito, Ali Ertürk, Thomas C. Mettenleiter, Barbara G. Klupp, Remco T. A. Megens, Sabine Steffens, Jaroslav Pelisek, Hans-Henning Eckstein, Robert Kleemann, Livia H

NATURE Article: Foundation models for generalist medical artificial intelligence

2023-05-12

Author's information: Michael Moor, Oishi Banerjee, Zahra Shakeri Hossein Abad, Harlan M. Krumholz, Jure Leskovec, Eric J. Topol & Pranav Rajpurkar

Recommended reading: Woman spends 500 days alone in a cave – how extreme isolation can alter your sense of time

2023-04-28

NATURE Article: Evidence of near-ambient superconductivity in a N-doped lutetium hydride

2023-03-10

Author information: Nathan Dasenbrock-Gammon, Elliot Snider, Raymond McBride, Hiranya Pasan, Dylan Durkee, Nugzari Khalvashi-Sutter, Sasanka Munasinghe, Sachith E. Dissanayake, Keith V. Lawler, Ashkan Salamat & Ranga P. Dias

NATURE Article: Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy

2023-03-10

Author information: Xiaoying Chen, Maria Firulyova, Melissa Manis, Jasmin Herz, Igor Smirnov, Ekaterina Aladyeva, Chanung Wang, Xin Bao, Mary Beth Finn, Hao Hu, Irina Shchukina, Min Woo Kim, Carla M. Yuede, Jonathan Kipnis, Maxim N. Artyomov, Jason D. Ulrich & David M. Holtzman

Nature Materials paper: An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection

2023-02-17

The surge of fast-spreading SARS-CoV-2 mutated variants highlights the need for fast, broad-spectrum strategies to counteract viral infections. In this work, we report a physical barrier against SARS-CoV-2 infection based on an inhalable bioadhesive hydrogel, named spherical hydrogel inhalation for enhanced lung defence (SHIELD). Conveniently delivered via a dry powder inhaler, SHIELD particles form a dense hydrogel network that coats the airway, enhancing the diffusional barrier properties and

Science Immunology paper: A central role for STAT5 in the transcriptional programing of T helper cell metabolism

2022-11-25

Author information: ALEJANDRO V. VILLARINO, ARIAN DJ LAURENCE, FRED P. DAVIS, LUIS NIVELO, STEPHEN R. BROOKS, HONG-WEI SUN, KAN JIANG, BEHDAD AFZALI, DANIELA FRASCA, LOTHAR HENNIGHAUSEN, YUKA KANNO , AND JOHN J. O’SHEA

NATURE Article: Surface reaction for efficient and stable inverted perovskite solar cells

2022-11-11

Author information: Qi Jiang, Jinhui Tong, Yeming Xian, Ross A. Kerner, Sean P. Dunfield, Chuanxiao Xiao, Rebecca A. Scheidt, Darius Kuciauskas, Xiaoming Wang, Matthew P. Hautzinger, Robert Tirawat, Matthew C. Beard, David P. Fenning, Joseph J. Berry, Bryon W. Larson, Yanfa Yan & Kai Zhu

NATURE Article: Hydroxamic acid pre-adsorption raises the efficiency of cosensitized solar cells

2022-11-04

Dye-sensitized solar cells (DSCs) convert light into electricity by using photosensitizers adsorbed on the surface of nanocrystalline mesoporous titanium dioxide (TiO2) films along with electrolytes or solid charge-transport materials. They possess many features including transparency, multicolour and low-cost fabrication, and are being deployed in glass facades, skylights and greenhouses. Recent development of sensitizers, redox mediators?and device structures?has improved the performance of DS

Nature Communications paper: A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

2022-07-22

The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon receptor dual agonist, in Chinese patients with T2D.